Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 8/20 | 0.62 |
| ▸ | CES2 | O00748 | 2/20 | 0.56 |
| ▸ | CES1 | P23141 | 2/20 | 0.56 |
| ▸ | F3 | P13726 | 1/20 | 0.47 |
| ▸ | PNLIP | P16233 | 1/20 | 0.47 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.47 |
| ▸ | NOS2 | P35228 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Taraxerone SCHEMBL23929104 | 1.00 | PTPN1 (0.62) | PTPN1CES2CES1F3PNLIP | |
| SCHEMBL29934987 | 0.83 | CES2 (0.47) | PTPN1CES2CES1F3PNLIP | |
| SCHEMBL30544824 | 0.79 | PTPN1 (0.66) | PTPN1CES2CES1PTPN2 | |
| Taraxerol SCHEMBL569463 | 0.77 | PTPN1 (1.00) | PTPN1CES1F3PTPN2RELA | |
| Taraxerol SCHEMBL14047708 | 0.77 | PTPN1 (1.00) | PTPN1CES1F3PTPN2RELA | |
| Taraxerol SCHEMBL15491005 | 0.77 | PTPN1 (1.00) | PTPN1CES1F3PTPN2RELA | |
| Taraxerol SCHEMBL15491002 | 0.77 | PTPN1 (1.00) | PTPN1CES1F3PTPN2RELA | |
| Taraxerol SCHEMBL569464 | 0.77 | PTPN1 (1.00) | PTPN1CES1F3PTPN2RELA | |
| Taraxerol SCHEMBL21264264 | 0.77 | PTPN1 (1.00) | PTPN1CES1F3PTPN2RELA | |
| SCHEMBL19473411 | 0.75 | PTPN1 (0.71) | PTPN1PTPN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 201 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12134787-B2 | Method for increasing the yield of oxidosqualene, triterpenes and/or triterpenoids and host cell therefore | FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V. (DE) | 2024-11-05 | — | — | US | claimed |
| US-20230172945-A1 | APPLICATION OF COMPOUNDS IN CONTROLLING OR KILLING MITES | Guangzhou Medical University Property Operation Limited Corporation (CN) | 2023-06-08 | — | — | US | claimed |
| US-20230165921-A1 | USE OF DANDELION AND MONOMER COMPOUNDS THEREOF FOR KILLING MITES | Guangzhou Medical University Property Operation Limited Corporation (CN) | 2023-06-01 | — | — | US | claimed |
| EP-4129314-A1 | USE OF DANDELION AND MONOMER COMPOUNDS THEREOF FOR KILLING MITES | Smilebiotek Zhuhai Limited (CN) | 2023-02-08 | — | — | EP | claimed |
| EP-4122468-A1 | APPLICATION OF COMPOUNDS IN CONTROLLING OR KILLING MITES | Smilebiotek Zhuhai Limited (CN) | 2023-01-25 | — | — | EP | claimed |
| US-20210071150-A1 | METHOD FOR INCREASING THE YIELD OF OXIDOSQUALENE, TRITERPENES AND/OR TRITERPENOIDS AND HOST CELL THEREFORE | WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTER (DE) | 2021-03-11 | — | — | US | claimed |
| EP-3775181-A1 | METHOD FOR INCREASING THE YIELD OF OXIDOSQUALENE, TRITERPENES AND/OR TRITERPENOIDS AND HOST CELL THEREFORE | Fraunhofer Gesellschaft zur Förderung der Angewand (DE) | 2021-02-17 | — | — | EP | claimed |
| WO-2019197327-A1 | METHOD FOR INCREASING THE YIELD OF OXIDOSQUALENE, TRITERPENES AND/OR TRITERPENOIDS AND HOST CELL THEREFORE | FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V. (DE) | 2019-10-17 | — | — | WO | claimed |
| CN-110122878-A | A kind of relieving alcoholism and protecting liver composition and preparation method and application containing probiotics | 山东圣奥生物科技有限公司 | 2019-08-16 | — | — | CN | claimed |
| CN-108578414-A | A kind of pharmaceutical composition and preparation method thereof for treating cerebral arterial thrombosis | 任士洪 | 2018-09-28 | — | — | CN | claimed |
| US-20090022821-A1 | COMPOSITIONS FROM WAX MYRTLE FOR THE TREATMENT OF CANCER, CARDIOVASCULAR AND INFLAMMATORY DISEASES | DEV INDERJIT KUMAR | 2009-01-22 | — | — | US | claimed |
| CN-1572307-A | Cola containing cactus and reishi mushroom | LIAO CHANGPING (CN) | 2005-02-02 | — | — | CN | claimed |
| WO-2025088039-A1 | HIGHLY CONCENTRATED DERMALLY APPLICABLE PERMETHRIN PREPARATION WITH AN INCREASED DRUG LOAD IN THE TARGET COMPARTMENT FOR IMPROVED TREATMENT OF ECTOPARASITE INFESTATION | INFECTOPHARM ARZNEIMITTEL UND CONSILIUM GMBH (DE) | 2025-05-01 | — | — | WO | disclosed |
| EP-4545067-A1 | HIGHY DOSED DERMALLY APPLICABLE PERMETHRIN PREPARATION HAVING AN INCREASED DRUGLOAD IN THE TARGET COMPARTIMENT FOR IMPROVED TREATMENT OF ECTOPARASITE INFESTATION | Infectopharm Arzneimittel und Consilium GmbH (DE) | 2025-04-30 | — | — | EP | disclosed |
| US-12134787-B2 | Method for increasing the yield of oxidosqualene, triterpenes and/or triterpenoids and host cell therefore | FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V. (DE) | 2024-11-05 | — | — | US | disclosed |
| US-20230172945-A1 | APPLICATION OF COMPOUNDS IN CONTROLLING OR KILLING MITES | Guangzhou Medical University Property Operation Limited Corporation (CN) | 2023-06-08 | — | — | US | disclosed |
| CN-100361598-C | Xianling noodle | CHANGPING LIAO (CN) | 2008-01-16 | — | — | CN | disclosed |
| CN-1572307-A | Cola containing cactus and reishi mushroom | LIAO CHANGPING (CN) | 2005-02-02 | — | — | CN | disclosed |
| CN-1466891-A | Xianling noodle | 廖常萍 | 2004-01-14 | — | — | CN | disclosed |
| US-20030165579-A1 | Euphorbia antiquorum extract, a pharmaceutical composition containing the same and methods for treatment of cancers | CHENG, WEN-CHING (TW) | 2003-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230172945-A1 | APPLICATION OF COMPOUNDS IN CONTROLLING OR KILLING MITES | DSTN, DDT, TYR | PTPN1 1490/4885CES2 2771/4885CES1 1781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.